VarmX B.V.
VarmX is a biotech company focused on developing innovative approaches for the reversal of anticoagulation, specifically targeting FXa-DOACs and inherited coagulation disorders. Their mission is to revolutionize the treatment of severe bleeding through a fast, safe, and effective medicine, with their lead compound VMX-C001 designed to rapidly restore blood coagulation in patients taking Factor Xa inhibitors. The company aims to stop severe bleeding, eliminate bleeding risks during surgery, and improve patient outcomes with their novel therapies.
Industries
Nr. of Employees
small (1-50)
VarmX B.V.
Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands
Products
Modified recombinant human factor X therapeutic (lead clinical candidate)
A modified recombinant human coagulation factor X protein designed to be insensitive to inhibition by factor Xa direct oral anticoagulants and to restore coagulation in patients requiring reversal of FXa-DOAC anticoagulation.
Modified recombinant human factor X therapeutic (lead clinical candidate)
A modified recombinant human coagulation factor X protein designed to be insensitive to inhibition by factor Xa direct oral anticoagulants and to restore coagulation in patients requiring reversal of FXa-DOAC anticoagulation.
Services
Partnerships to conduct preclinical efficacy studies, coagulation assay development and translational biomarker assessments for anticoagulation-reversal therapeutic programs.
Design and execution of early-phase clinical studies including randomized, placebo-controlled single-ascending-dose designs with integrated PK/PD, safety and immunogenicity assessments.
Presentation of data at scientific conferences and engagement with investors and partnering networks to support program funding and strategic partnerships.
Partnerships to conduct preclinical efficacy studies, coagulation assay development and translational biomarker assessments for anticoagulation-reversal therapeutic programs.
Design and execution of early-phase clinical studies including randomized, placebo-controlled single-ascending-dose designs with integrated PK/PD, safety and immunogenicity assessments.
Presentation of data at scientific conferences and engagement with investors and partnering networks to support program funding and strategic partnerships.
Expertise Areas
- Anticoagulation reversal therapies
- Hemostasis and thrombosis research
- Clinical development (Phase 1 trials)
- Coagulation assay development and validation
Key Technologies
- Recombinant protein engineering
- Preclinical bleeding models (cynomolgus monkey liver injury)
- Diluted Russell viper venom time (dRVVT) assay
- Diluted prothrombin time (dPT) assay
News & Updates
VarmX to attend Jefferies London Healthcare Conference
VarmX will be attending the Jefferies London Healthcare Conference from 19-21 November 2024, to meet with potential investors.
VarmX to present at LSX Investival Showcase
VarmX will present at the LSX Investival Showcase in London on 18 November 2024, to showcase their business and growth plans to potential investors.
VarmX to attend JP Morgan Healthcare Week
VarmX will be attending the JP Morgan Healthcare Conference and Biotech Showcase week in San Francisco from 13-16 January 2025, to engage with potential investors and partners.
VarmX to present two abstracts at ISTH 2023 Congress
VarmX will present two abstracts at the ISTH Congress in Montreal, June 24-28, 2023, including data on VMX-C001's efficacy and monitoring assays.
VarmX presents new data at ISTH 2024
VarmX presented new data at the ISTH Congress in Bangkok, showing that VMX-C001 rapidly restores coagulation in a bleeding model.
VarmX awarded €15 Mln follow-on equity investment by the EIC Accelerator
VarmX received a €15 million follow-on investment from the European Innovation Council (EIC) to further develop VMX-C001.
VarmX to attend Jefferies London Healthcare Conference
VarmX will be attending the Jefferies London Healthcare Conference from 19-21 November 2024, to meet with potential investors.
VarmX to present at LSX Investival Showcase
VarmX will present at the LSX Investival Showcase in London on 18 November 2024, to showcase their business and growth plans to potential investors.
VarmX to attend JP Morgan Healthcare Week
VarmX will be attending the JP Morgan Healthcare Conference and Biotech Showcase week in San Francisco from 13-16 January 2025, to engage with potential investors and partners.
VarmX to present two abstracts at ISTH 2023 Congress
VarmX will present two abstracts at the ISTH Congress in Montreal, June 24-28, 2023, including data on VMX-C001's efficacy and monitoring assays.
VarmX presents new data at ISTH 2024
VarmX presented new data at the ISTH Congress in Bangkok, showing that VMX-C001 rapidly restores coagulation in a bleeding model.
VarmX awarded €15 Mln follow-on equity investment by the EIC Accelerator
VarmX received a €15 million follow-on investment from the European Innovation Council (EIC) to further develop VMX-C001.